Download
s00432-021-03870-6.pdf 1005,76KB
WeightNameValue
1000 Titel
  • Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients
1000 Autor/in
  1. Purde, Mette-Triin |
  2. Niederer, Rebekka |
  3. Wagner, Nikolaus B. |
  4. Diem, Stefan |
  5. Berner, Fiamma |
  6. Hasan Ali, Omar |
  7. Hillmann, Dorothea |
  8. Bergamin, Irina |
  9. Joerger, Markus |
  10. Risch, Martin |
  11. Niederhauser, Christoph |
  12. Lenz, Tobias L. |
  13. Früh, Martin |
  14. Risch, Lorenz |
  15. Semela, David |
  16. Flatz, Lukas |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-12-07
1000 Erschienen in
1000 Quellenangabe
  • 148(3):647-656
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03870-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881258/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients.!##!Methods!#!Data from a prospective biomarker cohort comprising melanoma and non-small cell lung cancer (NSCLC) patients were used to analyze the incidence of ICI-induced hepatitis, putatively associated factors, and outcome.!##!Results!#!40 patients with melanoma and 91 patients with NSCLC received ICI between July 2016 and May 2019. 11 patients developed ICI-induced hepatitis (8.4%). Prior to treatment, 45.5% of patients in the hepatitis cohort and 43.8% of the control cohort showed elevated titers of autoantibodies commonly associated with autoimmune liver diseases (p = 0.82). We found two nominally significant associations between the occurrence of ICI-induced hepatitis and HLA alleles associated with autoimmune liver diseases among NSCLC patients. Of note, significantly more patients with ICI-induced hepatitis developed additional irAEs in other organs (p = 0.0001). Neither overall nor progression-free survival was affected in the hepatitis group.!##!Conclusion!#!We found nominally significant associations of ICI-induced hepatitis with two HLA alleles. ICI-induced hepatitis showed no correlation with liver-specific autoantibodies, but frequently co-occurred with irAEs affecting other organs. Unlike other irAEs, ICI-induced hepatitis is not associated with a better prognosis.
1000 Sacherschließung
lokal Switzerland/epidemiology [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Autoantibodies/immunology [MeSH]
lokal Drug-induced liver injury
lokal Male [MeSH]
lokal Hepatitis/immunology [MeSH]
lokal Immune Checkpoint Inhibitors/adverse effects [MeSH]
lokal Melanoma/pathology [MeSH]
lokal Lung Neoplasms/immunology [MeSH]
lokal Case-Control Studies [MeSH]
lokal Drug-related side effects and adverse reactions
lokal Autoantibodies
lokal Melanoma/drug therapy [MeSH]
lokal Carcinoma, Non-Small-Cell Lung/pathology [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Checkpoint inhibitors
lokal Original Article – Cancer Research
lokal Adult [MeSH]
lokal Autoantibodies/blood [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Hepatitis/epidemiology [MeSH]
lokal Middle Aged [MeSH]
lokal Hepatitis/blood [MeSH]
lokal Survival Rate [MeSH]
lokal Melanoma/immunology [MeSH]
lokal Biomarkers, Tumor/blood [MeSH]
lokal Prognosis [MeSH]
lokal Hepatitis/etiology [MeSH]
lokal Lung Neoplasms/pathology [MeSH]
lokal Biomarkers, Tumor/immunology [MeSH]
lokal Carcinoma, Non-Small-Cell Lung/immunology [MeSH]
lokal Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH]
lokal Lung Neoplasms/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UHVyZGUsIE1ldHRlLVRyaWlu|https://frl.publisso.de/adhoc/uri/TmllZGVyZXIsIFJlYmVra2E=|https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBOaWtvbGF1cyBCLg==|https://frl.publisso.de/adhoc/uri/RGllbSwgU3RlZmFu|https://frl.publisso.de/adhoc/uri/QmVybmVyLCBGaWFtbWE=|https://frl.publisso.de/adhoc/uri/SGFzYW4gQWxpLCBPbWFy|https://frl.publisso.de/adhoc/uri/SGlsbG1hbm4sIERvcm90aGVh|https://frl.publisso.de/adhoc/uri/QmVyZ2FtaW4sIElyaW5h|https://frl.publisso.de/adhoc/uri/Sm9lcmdlciwgTWFya3Vz|https://frl.publisso.de/adhoc/uri/UmlzY2gsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/TmllZGVyaGF1c2VyLCBDaHJpc3RvcGg=|https://frl.publisso.de/adhoc/uri/TGVueiwgVG9iaWFzIEwu|https://frl.publisso.de/adhoc/uri/RnLDvGgsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/UmlzY2gsIExvcmVueg==|https://frl.publisso.de/adhoc/uri/U2VtZWxhLCBEYXZpZA==|https://orcid.org/0000-0001-9683-8390
1000 Hinweis
  • DeepGreen-ID: f02ed8fa00e545a38ba1ec933ff5b749 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6446876.rdf
1000 Erstellt am 2023-04-28T14:27:02.010+0200
1000 Erstellt von 322
1000 beschreibt frl:6446876
1000 Zuletzt bearbeitet 2023-10-20T19:10:47.655+0200
1000 Objekt bearb. Fri Oct 20 19:10:47 CEST 2023
1000 Vgl. frl:6446876
1000 Oai Id
  1. oai:frl.publisso.de:frl:6446876 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source